

1 **Metabolomic biomarkers from patients with Barth syndrome treated**
2 **with elamipretide: insights from the TAZPOWER study**

3

4 Peter J. Oates¹, David A. Brown², Hilary J. Vernon^{3,*}, Jon A. Gangoiti⁴, and Bruce A.
5 Barshop⁴

6

7 ¹ Oates Biomedical Consulting, Old Lyme, Connecticut, United States of America

8 ² Stealth BioTherapeutics, Newton, Massachusetts, United States of America

9 ³ Johns Hopkins University, Baltimore, Maryland, United States of America

10 ⁴ University of California San Diego, San Diego, California, United States of America

11

12 * **Corresponding author:** hvernon1@jhmi.edu

13

14 **Abstract length:** 293 words

15 **Text length:** 2545 words

16 **No. of references:** 52

17 **No. of graphics:** 7 (1 table/6 figures)

18

19 **Summary points**

20

21 • Exploratory targeted metabolomic analyses of plasma and urine were performed after
22 a double-blind, crossover trial in patients with Barth syndrome receiving elamipretide
23 or placebo for 12 weeks.

24 • Among 51 “energy-linked” metabolites analyzed in both plasma and urine, prominent
25 changes were observed in metabolites associated with fat metabolism.

26 • Collectively, plasma medium-chain (C6-C12) acylcarnitines were reduced after 12
27 weeks of elamipretide treatment in patients with Barth syndrome.

28 • Urinary acylcarnitine concentrations were also lowered with elamipretide in Barth
29 syndrome patients, most prominently for shorter chain acylcarnitines.

30 • Elamipretide for 12 weeks also trended to lower 3-methylglutaconate and the ketone
31 body 3-hydroxybutyrate, although these decreases did not reach statistical
32 significance.

33 • Elamipretide also caused a significant rise in plasma taurine, which has been
34 previously reported to be low in Barth syndrome patients.

35 • These metabolite changes may be consistent with improved mitochondrial function that
36 precedes the functional benefits observed in patients with Barth syndrome after longer-
37 term therapy.

38

39 **Abstract**

40

41 **Background**

42 Barth syndrome is an inherited disorder that results from pathogenic mutations in *TAZ*,
43 the gene responsible for encoding tafazzin, an enzyme that remodels the mitochondrial
44 phospholipid cardiolipin. Barth syndrome is characterized by heart and skeletal muscle
45 myopathy, growth delay, and neutropenia among other features. The TAZPOWER clinical
46 trial investigated the effects of the mitochondria-targeting peptide elamipretide in patients
47 with Barth syndrome.

48 **Methods and findings**

49 TAZPOWER included a randomized, double-blind, crossover study of 12 weeks treatment
50 with elamipretide or placebo in 12 patients with Barth syndrome. A broad spectrum of
51 plasma and urine metabolites were measured using liquid chromatography-tandem mass
52 spectrometry at baseline and after 12 weeks treatment with elamipretide or placebo. Of
53 51 “energy-linked” metabolites analyzed, we highlight here the effects of elamipretide on
54 the plasma and urinary concentrations of several metabolites previously observed to be
55 abnormal in patients with Barth syndrome. Elamipretide treatment was associated with
56 significantly lowered medium- and short-chain acylcarnitines in plasma and urine,
57 respectively ($p < 0.05$). Acetylcarnitine, 3-hydroxybutyrate, and 3-methylglutaconate
58 trended to decrease after 12 weeks of elamipretide, but these trends did not reach
59 statistical significance. After 12 weeks of treatment, elamipretide had no discernible effect
60 on four amino acids previously characterized as having abnormal concentrations in
61 patients with Barth syndrome. Lastly, elamipretide caused a significant rise in plasma

62 taurine concentrations, an amino acid which has been observed to be decreased in
63 patients with Barth syndrome.

64 **Conclusions**

65 As evidenced by reduced plasma and urinary content of acylcarnitines and trends for
66 lowered ketone body 3-hydroxybutyrate, fat metabolism in Barth syndrome appears to be
67 modified after 12 weeks of elamipretide treatment. Overall, these data are consistent with
68 the improved mitochondrial function that may precede functional benefits with a longer
69 duration of therapy with elamipretide in patients with Barth syndrome.

70

71 **Trial registration**

72 ClinicalTrials.gov NCT03098797.

73

74 **Introduction**

75

76 First described in 1983 [1], Barth syndrome is a rare and potentially fatal X-linked disease
77 characterized by cardiomyopathy, skeletal muscle weakness, growth delays, and cyclic
78 neutropenia [2]. It is caused by defects in *TAZ*, a gene whose product, tazzaflin, is an
79 enzyme essential for cardiolipin biosynthesis and mitochondrial function (for review see
80 Sabbah [3]). There are no approved therapies for Barth syndrome and a paucity of reliable
81 biomarkers with which to understand disease progression and appropriate treatment in
82 this patient population.

83 Metabolite measurements in clinical studies have long provided a method for
84 understanding pharmacological mechanisms and for biomarker discovery [4,5]. Recent
85 metabolic and metabolomic studies in Barth syndrome have shown pathological
86 alterations in concentrations of acylcarnitines, products of amino acid catabolism (such
87 as 3-methylglutaconate), the ketone body 3-hydroxybutyrate, certain circulating amino
88 acids, and taurine [6-9]. Whether or not these metabolites can be altered with a putative
89 therapy in Barth syndrome has not been previously explored.

90 The TAZPOWER study was designed to determine the safety and efficacy of
91 elamipretide in patients with Barth syndrome [10]. Elamipretide is a mitochondria-
92 targeting peptide that interacts with cardiolipin, an essential mitochondrial phospholipid
93 that is synthesized *de novo* [11,12]. Barth syndrome is caused by pathogenic mutations
94 in the *TAZ* gene that encodes for tafazzin, a transacylase required for cardiolipin
95 remodeling. Patients with Barth syndrome have increased levels of immature cardiolipin
96 (monolysocardiolipin), decreased remodeled cardiolipin, and resulting mitochondrial

97 dysfunction [3]. Across numerous pre-clinical models, elamipretide has been shown to
98 improve mitochondrial structure and function in a cardiolipin-dependent manner [13,14],
99 resulting in improved heart and skeletal muscle function.

100 The present report highlights results from an exploratory analysis of plasma and urinary
101 metabolic data obtained in the double-blind, crossover part of the TAZPOWER study.

102

103 **Methods**

104

105 **Trial design**

106

107 The protocol for the TAZPOWER study was approved by the local institutional review
108 board committee [Johns Hopkins University IRB protocol IRB00124162: "A Phase 2
109 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety,
110 Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in
111 Subjects with Genetically Confirmed Barth Syndrome"]. The study conformed with the
112 principles of the Declaration of Helsinki and was prospectively registered with
113 clinicaltrials.gov (NCT03098797).

114 TAZPOWER includes a 28-week, randomized, double-blind, placebo-controlled,
115 crossover assessment of the safety and efficacy of elamipretide in Barth syndrome
116 patients [10]. Twelve male patients ages ≥ 12 (range, 12-35) years with genetically
117 confirmed Barth syndrome were randomized (1:1) to elamipretide 40 mg once daily or
118 placebo for 12 weeks (period 1) followed by a 4-week washout period, after which patients
119 were crossed over to the alternate treatment for a further 12 weeks (period 2). Patients

120 were ambulatory but with impaired 6-minute walk test (mean, 395.5 meters; range, 313-
121 495 meters). Vital signs, including electrocardiogram parameters, were within normal
122 limits. The most commonly reported comorbid medical conditions were cardiomyopathy
123 (67%), neutropenia (58%), and hypotonia (50%). Metabolites were analyzed from plasma
124 and urine samples to identify effects of elamipretide during the placebo and elamipretide
125 arms of the study. The trial design also included an open-label extension treatment period
126 with elamipretide for up to 168 additional weeks.

127

128 **Metabolite analyses**

129

130 Each patient provided blood and first morning void urine samples on four occasions:
131 pre-drug baseline period 1, end-of-period 1, pre-drug baseline period 2, and end-of-period
132 2. Plasma ($n = 48$) and urine ($n = 48$) samples were shipped frozen on dry ice to the
133 Biochemical Genetics Laboratory, University of California San Diego for analysis by liquid
134 chromatography-electrospray ionization tandem mass spectrometry per established
135 protocols [15]. Of 378 analytes which were quantified and normalized to internal
136 standards, we focused on 51 metabolites associated with energy metabolism. In addition,
137 values for urine specimens were normalized to urinary creatinine.

138 One Barth syndrome patient was overtly diabetic throughout the study [mean \pm
139 standard deviation blood glucose values 9.1 ± 1.6 mmol/L ($n = 10$) vs 5.0 ± 0.5 mmol/L
140 ($n = 43$) in the other 11 patients]. Since chronic hyperglycemia and diabetes are well
141 known to be associated with altered metabolomic profiles and dysfunctional mitochondrial
142 metabolism [16-18], metabolomic data for the patient with diabetes were excluded from

143 the final exploratory analyses, so the complete dataset sample number per metabolite
144 became 44.

145 The data reported herein represent highlights with respect to some previously identified
146 metabolites known to be altered in Barth syndrome [6-9]. The Δ value for a given
147 metabolite was calculated as the 12-week change from baseline in metabolite
148 concentration with elamipretide treatment minus the 12-week change from baseline with
149 placebo treatment.

150

151 **Statistical analyses**

152

153 The effects of each arm were compared to each other using a paired Student's *t*-test.
154 Multiple related metabolites were analyzed using a two-way ANOVA, with main factors of
155 metabolite and elamipretide effects, as well as analysis for any interaction among main
156 factors. One metabolite datapoint (in the plasma taurine dataset) was excluded from
157 analysis because it was judged to be an aberrant value that was 8 standard deviations
158 from the mean, resulting in only 10 patients being evaluated for this metabolite. For all
159 other metabolites, 11 patients were evaluated. Data are presented as means \pm standard
160 error. Significance was noted using an alpha level of $p < 0.05$.

161

162

163 **Results**

164

165 **Plasma acylcarnitines**

166

167 Elevated plasma acylcarnitines have been previously reported in Barth syndrome [9] and
168 are commonly observed in other pathologies, in particular cardiomyopathies [19-21]. The
169 changes in circulating levels of medium chain (C6-C12) acylcarnitines identified from
170 TAZPOWER are presented in Fig 1. Patient-specific changes in each of the four
171 acylcarnitines are shown in Fig 1A, with the quantified data plotted in Fig 1B. There was
172 a statistically significant decrease in plasma medium chain acylcarnitines (C6-C12
173 combined) in the elamipretide-treated arm of the study compared to placebo ($p = 0.007$
174 for elamipretide effect).

175

176 **Urinary acylcarnitines**

177

178 Urinary acylcarnitine levels in urine (normalized to creatinine levels) are presented in Fig
179 2. There was also a statistically significant reduction in urinary acylcarnitines (C6-C8) with
180 elamipretide compared to placebo ($p = 0.0499$ for elamipretide effect).

181

182 **Acetylcarnitine**

183

184 Acetylcarnitine (C2-crn) is typically the most abundant circulating acylcarnitine (present
185 in micromolar concentrations) and has previously been found to be increased in Barth

186 syndrome [9]. There was a trend for decreased acetylcarnitine levels in both plasma and
187 urine (normalized to creatinine) following elamipretide treatment, but this decrease did
188 not reach statistical significance ($p = 0.13$ for elamipretide effect) [Fig 3].

189

190 **3-Methylglutaconate**

191

192 Plasma and urinary levels of 3-methylglutaconate are shown in Fig 4.
193 3-Methylglutaconate has been observed to be increased in most, but not all, individuals
194 with Barth syndrome [2,7,8,22]. In the current study, there was a strong trend for
195 decreased 3-methylglutaconate concentration in both plasma and urine, but this did not
196 reach statistical significance compared to placebo (Fig 4, $p = 0.084$ for elamipretide
197 effect).

198

199 **3-Hydroxybutyrate**

200

201 Changes in plasma levels of the ketone body 3-hydroxybutyrate are shown in Fig 5.
202 3-Hydroxybutyrate (also called β -hydroxybutyrate) has been shown to be robustly
203 increased in Barth syndrome [9], as well as in several heart failure studies [23,24]. In the
204 current study, there was a strong trend for decreased plasma 3-hydroxybutyrate following
205 elamipretide treatment, although this trend did not reach statistical significance compared
206 to placebo ($p = 0.07$ for elamipretide effect).

207

208

209 **Plasma amino acids**

210

211 Differences in plasma concentrations of the amino acids arginine, asparagine, proline,
212 and tyrosine for Barth syndrome patients versus controls have been previously reported
213 [6-9]. In the current study plasma concentrations of proline ($125 \pm 4 \mu\text{mol/L}$), tyrosine (57
214 $\pm 3 \mu\text{mol/L}$), and arginine ($54 \pm 4 \mu\text{mol/L}$) were within normal ranges previously seen in
215 non-Barth control patients [8]. Baseline plasma concentrations of asparagine were $173 \pm$
216 $8 \mu\text{mol/L}$, a heightened level that corroborates previous findings of elevated plasma
217 asparagine in Barth syndrome [8]. Changes from baseline after 12 weeks of treatment
218 with either placebo or elamipretide for these four metabolites are shown in Table 1. There
219 were no statistically significant changes in the elamipretide arm for any of these four
220 amino acids.

221

222 **Plasma taurine**

223

224 Taurine is the most abundant free amino acid in many tissues [25]. An estimated 70% of
225 total body taurine is localized to muscles and plays vital roles in mitochondrial, muscular,
226 and cardiovascular functions [26]. Deficiency of taurine has been linked to impaired
227 mitochondrial energy production and decreased exercise performance and can result in
228 cardiomyopathy [27]. In patients with Barth syndrome, plasma taurine was reported to be
229 36% lower than age-matched control values ($p = 0.07$) [9]. Changes in plasma taurine
230 levels in the present study are shown in Fig 6. Compared to placebo, circulating taurine

231 increased significantly in the elamipretide arm of the study ($p = 0.022$ for elamipretide
232 effect).

233

234 **Discussion**

235

236 In this study we analyzed energy-related metabolites from plasma and urine samples from
237 patients with Barth syndrome patients treated with elamipretide or placebo for 12 weeks.

238 There are several novel findings from the study. First, groups of plasma and urinary
239 acylcarnitines, commonly elevated as a result of mitochondrial dysfunction across
240 different myopathies, were significantly reduced following elamipretide treatment.

241 Second, 3-methylglutaconate and 3-hydroxybutyrate, metabolites previously reported to
242 be elevated in Barth syndrome, trended to decrease following 12 weeks treatment in the
243 elamipretide arm. Third, circulating levels of taurine, a substance essential for heart,
244 muscle, and mitochondrial function and previously reported to be subnormal in Barth
245 syndrome, was significantly increased after elamipretide treatment. Fourth, several amino
246 acids that have previously been shown to be altered in plasma of Barth syndrome patients
247 were not markedly affected by elamipretide treatment. Overall, these data indicate that
248 elamipretide positively affected mitochondrial bioenergetic function in patients with Barth
249 syndrome after 12 weeks of treatment.

250

251

252 **Acylcarnitines**

253

254 The elevation of plasma acylcarnitines observed in this study is consistent with previous
255 studies in Barth syndrome [9] as well as in other genetic mitochondrial diseases [21,22]
256 and cardiomyopathies [20,28]. In addition, a recent study demonstrated that Barth
257 syndrome patients display a severely blunted ability to upregulate fatty acid oxidation rate
258 in response to increased metabolic demand, and suggested that impaired fat oxidation
259 and oxidative phosphorylation contribute to bioenergetic dysfunction in Barth syndrome
260 [29].

261 Interestingly, elamipretide treatment was associated with a significant reduction in
262 plasma and urinary acylcarnitines (Figs 1 & 2). This suggests that elamipretide may be
263 improving mitochondrial fatty acid metabolism, as has been observed in numerous
264 cardiac [3,30] and non-cardiac [11] settings, as well as in Barth syndrome model systems
265 [31]. Improved β -oxidation of fatty acids with elamipretide may be attributed in principle
266 to a variety of factors: improved mitochondrial content [32], increased electron flow, and
267 supercomplex function in the mitochondrial inner membrane [33], reduction in ROS
268 formation [11,34], increased transport of fatty acids into the mitochondrial network through
269 cardiolipin-dependent pathways [35-37], or some combination thereof.

270 Altered cardiac fat catabolism has been found to precede changes in myocardial
271 function [38], and reductions in short- and medium-chain acylcarnitines have correlated
272 with improved cardiac function [39]. These data suggest that the reduction in plasma
273 acylcarnitines by elamipretide may reflect improved mitochondrial metabolism, potentially
274 leading to cardiac remodeling, a supposition supported by observations that longer term

275 elamipretide treatment was associated with increased stroke volume in Barth syndrome
276 patients [10].

277

278 **3-Methylglutaconate**

279

280 Elevated 3-methylglutaconate has been previously observed in Barth syndrome urine and
281 plasma [8,40], although levels of this metabolite have been variable across Barth
282 syndrome patients [2,7,22]. In contrast to the traditional view of 3-methylglutaconate as a
283 product of leucine catabolism, 3-methylglutaconate is currently hypothesized to be a more
284 general marker of inefficient fuel (acetyl-coenzyme A) utilization [41,42]. Accordingly, the
285 trend observed in the present study to lower 3-methylglutaconate with elamipretide (Fig
286 4) is consistent with improved efficiency of fuel utilization secondary to improved
287 mitochondrial bioenergetic status.

288

289 **3-Hydroxybutyrate**

290

291 The ketone body 3-hydroxybutyrate is considered to be an essential carbon source for
292 peripheral organs, particularly during conditions of metabolic stress [43]. This includes
293 heart failure, where myocardial catabolism of fatty acids decreases and increased ketone
294 catabolism are observed [23,24,44]. Concordantly, elevated plasma 3-hydroxybutyrate
295 has been identified as an important metabolite that differentiates Barth syndrome patients
296 from controls [9]. The strong trend for reduction in plasma 3-hydroxybutyrate with
297 elamipretide (Fig 5) may reflect improved mitochondrial catabolism of other carbon

298 substrates, e.g., fatty acids/acylcarnitines, and a reduced need for ketone-body derived
299 carbon sources to support energetics.

300

301 **Plasma amino acids**

302

303 Previous studies have identified abnormalities in several circulating amino acids as being
304 potentially characteristic of Barth syndrome. These include increases in plasma
305 asparagine, proline, and tyrosine, as well as a decrease in plasma arginine [6-9]. For
306 reasons that are not entirely clear in the present study the baseline plasma levels of these
307 amino acids were slightly different than previously observed [8,9], although the patients
308 enrolled in this study were approximately 10 years older than previously investigated and
309 were fasted overnight rather than for 3-4 hours. Several patients also received
310 supplemental arginine and citrulline at baseline. As tabulated in Table 1, elamipretide had
311 no significant effect on the amino acids listed.

312 A marked increase in plasma taurine was observed with elamipretide treatment (Fig
313 6). Taurine is a non-proteogenic amino acid that is considered essential for bioenergetics
314 and has been shown to be integral for heart and skeletal muscle physiology [26].
315 Deficiency in taurine is associated with the pathological development of a dilated
316 cardiomyopathy [27], providing rationale for the use of taurine supplementation for
317 patients with congestive heart failure [45]. Plasma taurine was reported to be depressed
318 by roughly 40% in Barth syndrome compared to age-matched controls [9]. Interestingly,
319 treatment with elamipretide significantly elevated plasma taurine concentrations in
320 patients with Barth syndrome (Fig 6). Since taurine is essential for proper mitochondrial

321 protein synthesis, which supports respiratory chain function, and suppresses excess
322 mitochondrial superoxide production [45], a rise in taurine may be presumably beneficial,
323 although an understanding of the mechanism(s) for this increase will require further
324 investigation.

325

326 **Integrated mechanistic insights**

327

328 Elamipretide is known to interact with cardiolipin and improve mitochondrial bioenergetics
329 across numerous preclinical models [11]. Cardiolipin is essential for mitochondrial
330 structure and function (for review see Schlame & Greenberg [12]). Protein complexes of
331 the electron transport chain (ETC), fission/fusion machinery, and transporters for
332 proteins/metabolites/nucleotides are all critically dependent on cardiolipin for optimal
333 function [35,46]. The loss of mature cardiolipin in Barth syndrome results in cascades of
334 cellular dysfunction, including loss of energy and redox homeostasis, calcium overload,
335 and cell death (for review see Sabbah [3]). Improved mitochondrial structure [13] and
336 ETC/supercomplex function [33] with elamipretide are also expected to improve the local
337 availability of oxidized FAD and NAD⁺ cofactors essential for complete β -oxidation of fats
338 [47,48]. All of these factors may contribute to the decreases in plasma and urine
339 acylcarnitines, as well as the trends for lower acetylcarnitine, 3-methylglutaconate, and
340 3-hydroxybutyrate observed in this study. Additionally, improved bioenergetic efficiency
341 would reduce the overall need for carbon substrates to support metabolism, which may
342 also contribute to the reductions in various metabolite concentrations observed. These
343 suppositions are in agreement with prior pre-clinical [11,13,49,50] and clinical [51,52] data

344 in settings other than Barth syndrome, indicating that elamipretide treatment can bring
345 about a more efficient bioenergetic state.

346

347 **Conclusions**

348

349 Overall, these TAZPOWER exploratory metabolomic data indicate that ELAM treatment
350 over a 12-week period in patients with Barth syndrome stabilized or reduced several
351 metabolic indicators of inefficient mitochondrial bioenergetic metabolism. Future work will
352 advance our understanding of acylcarnitines and other metabolites in the setting of Barth
353 syndrome. The observed responses to elamipretide may reflect early signs of improved
354 mitochondrial metabolism and could be consistent with increased cardiac stroke volume
355 in patients with Barth syndrome on longer-duration elamipretide therapy [10].

356

357 **Acknowledgments**

358

359 Third-party writing assistance was provided by Peter A. Todd, PhD, and James A. Shiffer,
360 RPh, of Write On Time Medical Communications, LLC, and was funded by Stealth
361 BioTherapeutics Inc. P.J.O. wishes to acknowledge the initiative and steadfast support
362 for this project provided by Dr. Mark J. Bamberger of Stealth BioTherapeutics Inc.

363

364 **Funding**

365

366 This work was funded by Stealth BioTherapeutics Inc.

367

368 **Disclosures**

369

370 P.J.O., H.J.V., J.A.G., and B.A.B. have served as consultants for Stealth BioTherapeutics
371 Inc. D.A.B. is employed by Stealth BioTherapeutics Inc and receives compensation and
372 equity/shares commensurate with this employment. P.J.O. owns stock and has received
373 share options commensurate with his consulting activities with Stealth BioTherapeutics
374 Inc.

375

376 **References**

377

- 378 1. Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IE,
379 Van't Veer-Korthof ET, et al. An X-linked mitochondrial disease affecting cardiac
380 muscle, skeletal muscle and neutrophil leucocytes. *J Neurol Sci.* 1983; 62(1-
381 3):327-55. doi: 10.1016/0022-510x(83)90209-5
- 382 2. Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al.
383 Barth syndrome. *Orphanet J Rare Dis.* 2013; 8:23. doi: 10.1186/1750-1172-8-23
- 384 3. Sabbah HN. Barth syndrome cardiomyopathy: targeting the mitochondria with
385 elamipretide. *Heart Fail Rev.* 2020. doi: 10.1007/s10741-020-10031-3. [Epub
386 ahead of print]
- 387 4. van den Berg RA, Rubingh CM, Westerhuis JA, van der Werf MJ, Smilde AK.
388 Metabolomics data exploration guided by prior knowledge. *Anal Chim Acta.* 2009;
389 651(2):173-81. doi: 10.1016/j.aca.2009.08.029
- 390 5. Kohler I, Hankemeier T, van der Graaf PH, Knibbe CAJ, van Hasselt JGC.
391 Integrating clinical metabolomics-based biomarker discovery and clinical
392 pharmacology to enable precision medicine. *Eur J Pharm Sci.* 2017; 109S:S15-21.
393 doi: 10.1016/j.ejps.2017.05.018
- 394 6. Cade WT, Spencer CT, Reeds DN, Waggoner AD, O'Connor R, Maisenbacher M,
395 et al. Substrate metabolism during basal and hyperinsulinemic conditions in
396 adolescents and young-adults with Barth syndrome. *J Inherit Metab Dis.* 2013;
397 36(1):91-101. doi: 10.1007/s10545-012-9486-x

- 398 7. Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A, et al.
399 Natural history of Barth syndrome: a national cohort study of 22 patients. *Orphanet*
400 *J Rare Dis.* 2013; 8:70. doi: 10.1186/1750-1172-8-70
- 401 8. Vernon HJ, Sandlers Y, McClellan R, Kelley RI. Clinical laboratory studies in Barth
402 syndrome. *Mol Genet Metab.* 2014; 112(2):143-7. doi:
403 10.1016/j.ymgme.2014.03.007
- 404 9. Sandlers Y, Mercier K, Pathmasiri W, Carlson J, McRitchie S, Sumner S, Vernon
405 HJ. Metabolomics reveals new mechanisms for pathogenesis in Barth syndrome
406 and introduces novel roles for cardiolipin in cellular function. *PLoS One.* 2016;
407 25;11(3):e0151802. doi: 10.1371/journal.pone.0151802
- 408 10. Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A
409 phase 2/3 randomized clinical trial followed by an open-label extension to evaluate
410 the effectiveness of elamipretide in Barth syndrome, a genetic disorder of
411 mitochondrial cardiolipin metabolism. *Genet Med.* 2020 Oct 20. doi:
412 10.1038/s41436-020-01006-8
- 413 11. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to
414 restore mitochondrial bioenergetics. *Br J Pharmacol.* 2014; 171:2029-50.
415 <https://doi.org/10.1111/bph.12461>
- 416 12. Schlame M, Greenberg ML. Biosynthesis, remodeling and turnover of
417 mitochondrial cardiolipin. *Biochim Biophys Acta.* 2017; 1862:3-7.
418 doi:10.1016/j.bbaliip.2016.08.010
- 419 13. Allen ME, Pennington ER, Perry JB, Dadoo S, Makrecka-Kuka M, Dambrova M, et
420 al. The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae

- 421 networks following cardiac ischemia reperfusion in rats. *Commun Biol.* 2020
422 17;3(1):389. doi: 10.1038/s42003-020-1101-3
- 423 14. Mitchell W, Ng EA, Tamucci JD, Boyd KJ, Sathappa M, Coscia A, et al. The
424 mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface
425 electrostatics as a key component of its mechanism of action. *J Biol Chem.* 2020;
426 295(21):7452-69. doi: 10.1074/jbc.RA119.012094
- 427 15. Gertsman I, Gangoiti JA, Barshop BA. Validation of a dual LC-HRMS platform for
428 clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted
429 metabolomics. *Metabolomics.* 2014; 10(2):312-23
- 430 16. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-
431 induced diabetic complications: from animal models to clinical trials. *Nat Rev Drug*
432 *Discov.* 2009; 8:417–29. doi.org/10.1038/nrd2476
- 433 17. Makrecka-Kuka M, Liepinsh E, Murray AJ, Lemieux H, Dambrova M, Tepp K, et al.
434 Altered mitochondrial metabolism in the insulin-resistant heart. *Acta Physiol (Oxf).*
435 2019; 228(3):e13430. doi.org/10.1111/apha.13430
- 436 18. Sowton AP, Griffin JL, Murray AJ. Metabolic profiling of the diabetic heart: toward
437 a richer picture. *Front Physiol.* 2019; 10:639. doi.org/10.3389/fphys.2019.00639
- 438 19. Thompson Legault J, Strittmatter L, Tardif J, Sharma R, Tremblay-Vaillancourt V,
439 Aubut C, et al. A metabolic signature of mitochondrial dysfunction revealed
440 through a monogenic form of Leigh syndrome. *Cell Rep.* 2015; 13(5):981-9. doi:
441 10.1016/j.celrep.2015.09.054
- 442 20. Ruiz M, Labarthe F, Fortier A, Bouchard B, Thompson Legault J, Bolduc V, et al.
443 Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid

- 444 metabolic dysregulation in mitochondria and beyond. *Am J Physiol Heart Circ*
445 *Physiol.* 2017; 313(4):H768-81. doi: 10.1152/ajpheart.00820.2016
- 446 21. Vissing CR, Dunø M, Wibrand F, Christensen M, Vissing J. Hydroxylated long-
447 chain acylcarnitines are biomarkers of mitochondrial myopathy. *J Clin Endocrinol*
448 *Metab.* 2019; 104(12):5968-76. doi: 10.1210/jc.2019-00721
- 449 22. Thompson WR, DeCroes B, McClellan R, Rubens J, Vaz FM, Kristaponis K, et al.
450 New targets for monitoring and therapy in Barth syndrome. *Genet Med.* 2016;
451 18(10):1001-10. doi: 10.1038/gim.2015.204
- 452 23. Bedi KC Jr, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al.
453 Evidence for intramyocardial disruption of lipid metabolism and increased
454 myocardial ketone utilization in advanced human heart failure. *Circulation.* 2016;
455 133(8):706-16. doi: 10.1161/CIRCULATIONAHA.115.017545
- 456 24. Murashige D, Jang C, Neinast M, Edwards JJ, Cowan A, Hyman MC, et al.
457 Comprehensive quantification of fuel use by the failing and nonfailing human heart.
458 *Science.* 2020; 370(6514):364-8. doi: 10.1126/science.abc8861
- 459 25. Ripps H, Shen W. Taurine: a "very essential" amino acid, *Mol Vis.* 2012; 18: 2673-
460 86
- 461 26. Seidel U, Huebbe P, Rimbach G. Taurine: a regulator of cellular redox
462 homeostasis and skeletal muscle function. *Mol Nutr Food Res.* 2019;
463 63(16):e1800569. doi: 10.1002/mnfr.201800569
- 464 27. Schaffer S, Jong CJ, Shetewy A, Ramila KC, Ito T. Impaired energy production
465 contributes to development of failure in taurine deficient heart. *Adv Exp Med Biol.*
466 2017; 975 Pt 1:435-46. doi: 10.1007/978-94-024-1079-2_35

- 467 28. Lanfear DE, Gibbs JJ, Li J, She R, Petucci C, Culver JA, et al. Targeted
468 metabolomic profiling of plasma and survival in heart failure patients. *JACC Heart*
469 *Fail.* 2017; 5(11):823-32. doi: 10.1016/j.jchf.2017.07.009
- 470 29. Cade WT, Bohnert KL, Peterson LR, Patterson BW, Bittel AJ, Okunade AL, et al.
471 Blunted fat oxidation upon submaximal exercise is partially compensated by
472 enhanced glucose metabolism in children, adolescents, and young adults with
473 Barth syndrome. *J Inherit Metab Dis.* 2019; 42(3):480-93. doi: 10.1002/jimd.12094
- 474 30. Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Expert
475 consensus document: mitochondrial function as a therapeutic target in heart
476 failure. *Nat Rev Cardiol.* 2017; 14(4):238-50. doi: 10.1038/nrcardio.2016.203
- 477 31. Wang Y, Palmfeldt J, Gregersen N, Makhov AM, Conway JF, Wang M, et al.
478 Mitochondrial fatty acid oxidation and the electron transport chain comprise a
479 multifunctional mitochondrial protein complex. *J Biol Chem.* 2019; 294(33):12380-
480 91. doi: 10.1074/jbc.RA119.008680
- 481 32. Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of
482 mitochondrial dynamics in the failing heart: normalization following long-term
483 therapy with elamipretide. *Cardiovasc Drugs Ther.* 2018; 32(4):319-28. doi:
484 10.1007/s10557-018-6805-y
- 485 33. Chatfield KC, Sparagna GC, Chau S, Phillips EK, Ambardekar AV, Aftab M, et al.
486 Elamipretide improves mitochondrial function in the failing human heart. *JACC*
487 *Basic Transl Sci.* 2019; 4(2):147-7. doi: 10.1016/j.jacbts.2018.12.005
- 488 34. Brown DA, Hale SL, Baines CP, del Rio CL, Hamlin RL, Yueyama Y, et al.
489 Reduction of early reperfusion injury with the mitochondria-targeting peptide

- 490 bendavia. *J Cardiovasc Pharmacol Ther.* 2014; 19(1):121-32. doi:
491 10.1177/1074248413508003
- 492 35. Claypool SM. Cardiolipin, a critical determinant of mitochondrial carrier protein
493 assembly and function. *Biochim Biophys Acta.* 2009; 1788(10):2059-68. doi:
494 10.1016/j.bbamem.2009.04.020
- 495 36. Zhao H, Li H, Hao S, Chen J, Wu J, Song C, et al. Peptide SS-31 upregulates
496 frataxin expression and improves the quality of mitochondria: implications in the
497 treatment of Friedreich ataxia. *Sci Rep.* 2017; 7(1):9840. doi: 10.1038/s41598-017-
498 10320-2
- 499 37. Li Y, Lou W, Grevel A, Böttinger L, Liang Z, Ji J, et al. Cardiolipin-deficient cells
500 have decreased levels of the iron-sulfur biogenesis protein frataxin. *J Biol Chem.*
501 2020; 295(33):11928-37. doi: 10.1074/jbc.RA120.013960
- 502 38. Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ, Des Rosiers C.
503 Metabolic and signaling alterations in dystrophin-deficient hearts precede overt
504 cardiomyopathy. *J Mol Cell Cardiol.* 2007; 43(2):119-29. doi:
505 10.1016/j.yjmcc.2007.05.015
- 506 39. Chen WS, Liu MH, Cheng ML, Wang CH. Decreases in circulating concentrations
507 of short-chain acylcarnitines are associated with systolic function improvement
508 after decompensated heart failure. *Int Heart J.* 2020; 61(5):1014-21. doi:
509 10.1536/ihj.20-053
- 510 40. Wortmann SB, Kluijtmans LAJ, Rodenburg RJ, Sass JO, Nouws J, van Kaauwen
511 EP et al. 3-Methylglutaconic aciduria – lessons from 50 genes and 977 patients. *J*
512 *Inherit Metab Dis.* 2013; 36:913-21. doi: 10.1007/s10545-012-9579-6

- 513 41. Ikon N, Ryan RO. On the origin of 3-methylglutaconic acid in disorders of
514 mitochondrial energy metabolism. *J Inherit Meta Dis.* 2016; 39:749-56.
515 doi.org/10.1007/s10545-016-9933-1
- 516 42. Jones DE, Perez L, Ryan RO. 3-Methylglutaric acid in energy metabolism. *Clin*
517 *Chim Acta.* 2020; 502:233-9. doi: 10.1016/j.cca.2019.11.006
- 518 43. Newman JC, Verdin E. β -Hydroxybutyrate: a signaling metabolite. *Annu Rev Nutr.*
519 2017; 37:51-76. doi.org/10.1146/annurev-nutr-071816-064916
- 520 44. Voros G, Ector J, Garweg C, Droogne W, Van Cleemput J, Peersman N, et al.
521 Increased cardiac uptake of ketone bodies and free fatty acids in human heart
522 failure and hypertrophic left ventricular remodeling. *Circ Heart Fail.* 2018;
523 11(12):e004953. doi: 10.1161/CIRCHEARTFAILURE.118.004953
- 524 45. Schaffer S, Kim HW. Effects and mechanisms of taurine as a therapeutic agent.
525 *Biomol Ther (Seoul).* 2018; 26:225-41. doi.org/10.4062/biomolther.2017.251
- 526 46. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial
527 dysfunction and disease. *Am J Physiol Cell Physiol.* 2007; 292(1):C33-44. doi:
528 10.1152/ajpcell.00243.2006
- 529 47. Watmough NJ, Bindoff LA, Birch-Machin MA, Jackson S, Bartlett K, et al. Impaired
530 mitochondrial beta-oxidation in a patient with an abnormality of the respiratory
531 chain. *Studies in skeletal muscle mitochondria. J Clin Invest.* 1990; 85:177-84.
- 532 48. Titov DV, Craican V, Goodman RP, Peng J, Grabarek Z, Mootha VK.
533 Complementation of mitochondrial electron transport chain by manipulation of the
534 NAD⁺/NADH ratio. *Science.* 2016; 352(6282):231-5. doi: 10.1126/science.aad4017

- 535 49. Righi V, Constantinou C, Mintzopoulos D, Khan N, Mupparaju SP, Rahme LG, et
536 al. Mitochondria-targeted antioxidant promotes recovery of skeletal muscle
537 mitochondrial function after burn trauma assessed by in vivo ³¹P nuclear magnetic
538 resonance and electron paramagnetic resonance spectroscopy. *FASEB J.* 2013;
539 27(6):2521-30. doi: 10.1096/fj.12-220764
- 540 50. Campbell MD, Duan J, Samuelson AT, Gaffrey MJ, Merrihew GE, Egertson JD, et
541 al. Improving mitochondrial function with SS-31 reverses age-related redox stress
542 and improves exercise tolerance in aged mice. *Free Radic Biol Med.* 2019;
543 134:268-81. doi: 10.1016/j.freeradbiomed.2018.12.031
- 544 51. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized
545 dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.
546 *Neurology.* 2018; 90(14):e1212-21. doi: 10.1212/WNL.0000000000005255
- 547 52. Oates PJ, Carr J. The impact of elamipretide on energy-linked urinary metabolites
548 in primary mitochondrial myopathy. *Muscle Nerve.* 2018; 58:S13
- 549

550 **Table**

551

552 **Table 1. Change in plasma amino acid concentrations after 12 weeks treatment**

553 **with elamipretide or placebo.**

Amino acid	Mean (SEM) change in concentration ($\mu\text{mol/L}$) after 12 weeks vs baseline		<i>p</i> -value
	Placebo	Elamipretide	
Asparagine	-32.7 (14.6)	-2.2 (17.5)	0.16
Proline	-5.1 (6.9)	0.35 (6.7)	0.60
Tyrosine	0.18 (4.3)	-1.3 (3.3)	0.81
Arginine	-3.7 (7.4)	-6.0 (5.5)	0.81


554 *Abbreviation:* SEM, standard error of the mean.

555 /

556 **Figure legends**

557 **Fig 1. Plasma medium-chain (C6-C12) acylcarnitines.** Change (Δ) in medium chain
558 acylcarnitines (6, 8, 10, and 12 carbon; C6-, C8-, C10-, and C12-crn, respectively) after
559 12 weeks treatment with placebo (PBO) or elamipretide (ELAM): **(A)** individual plots and
560 **(B)** mean (\pm SEM) [$n = 11$ per group]. *Elamipretide effect ($p = 0.007$; ANOVA) for all
561 medium chain (C6-C12) acylcarnitines combined.

562




563

564

565


566 **Fig 2. Urinary acylcarnitines.** Mean (\pm SEM) change (Δ) in acylcarnitines (6 and 8
567 carbon; C6-, and C8-crn, respectively) after 12 weeks treatment with placebo or
568 elamipretide ($n = 11$ per group). *Elamipretide effect ($p = 0.0499$; ANOVA) for C6 and C8
569 acylcarnitines combined.



570

571


572 **Fig 3. Plasma and urinary acetylcarnitine.** Mean (\pm SEM) change (Δ) in plasma and
573 urinary acetylcarnitine (C2-crn) after 12 weeks treatment with placebo or elamipretide (n
574 = 11 per group). Elamipretide effect ($p = 0.13$; ANOVA). Urinary acetylcarnitine
575 concentrations are adjusted for urinary creatinine concentration.



576

577


578 **Fig 4. Plasma and urinary 3-methylglutaconate.** Mean (\pm SEM) change (Δ) in plasma
579 and urinary 3-glutaconate (3-MGC) after 12 weeks treatment with placebo or elamipretide
580 ($n = 11$ per group). Elamipretide effect ($p = 0.084$; ANOVA). Urinary 3-methylglutaconate
581 concentrations are adjusted for urinary creatinine concentration.



582

583


584 **Fig 5. Plasma 3-hydroxybutyrate.** Individual changes (Δ) in plasma 3-hydroxybutyrate
585 (3-HB) concentration after 12 weeks treatment with placebo (PBO) or elamipretide
586 (ELAM) [$n = 11$]. Elamipretide effect ($p = 0.07$; paired t -test).



587

588

589 **Fig 6. Plasma taurine.** Individual changes (Δ) in plasma taurine concentration after 12
590 weeks treatment with placebo (PBO) or elamipretide (ELAM) [$n = 10$]. Elamipretide effect
591 ($p = 0.022$; paired t -test).



592